Agreement calls for a 34% equity investment in bioMérieux Japan and the subsequent creation of Sysmex bioMérieux.

Sysmex will take a 34% equity stake in bioMérieux Japan to form Sysmex bioMérieux. The new entity will promote and commercialize bioMérieux’ entire product range in Japan starting April 1, 2008.

bioMérieux has been operating in the Japanese clinical diagnostics and industrial testing market through bioMérieux Japan. As per the current arrangement, the joint venture will manage the regulatory filing and marketing activities for bioMérieux in Japan. The sales and customer service activities will be contracted out from the joint venture to Sysmex.

“bioMérieux Japan is number nineteen in the Japanese IVD market, while bioMérieux is number seven worldwide,” according to Stéphane Bancel, CEO of bioMérieux. “We have been lacking scale in several critical functions like commercial operations and customer service. By partnering with the number one diagnostics company in the Japanese market, we will bring bioMérieux’ innovative products to a broader Japanese customer base.”

Previous articleLFB Biotechnologies and GTC Biotherapeutics Expand Partnership to Include Coagulation Factor IX Program
Next articleInverness Inks Licensing Deal with BioCurex to Advance Oncology Diagnostics